{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:19:09Z","timestamp":1787905149936,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN276201200017C"],"award-info":[{"award-number":["HHSN276201200017C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"DOI":"10.1007\/s13318-026-01031-z","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:51:20Z","timestamp":1787903480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective and Time-Dependent Alterations in Cytochrome P450 (CYP) Enzyme Activity and Expression by Major Phytocannabinoids"],"prefix":"10.1007","author":[{"given":"Nupur","family":"Chaphekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Caritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugesh","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1021-4892","authenticated-orcid":false,"given":"Imam H.","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"3","key":"1031_CR1","first-page":"180","volume":"42","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P t. 2017;42(3):180\u20138.","journal-title":"P t"},{"key":"1031_CR2","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017."},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13722-015-0032-7","volume":"10","author":"KA Belendiuk","year":"2015","unstructured":"Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:10.","journal-title":"Addict Sci Clin Pract"},{"key":"1031_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1200269","volume":"14","author":"E Fordjour","year":"2023","unstructured":"Fordjour E, Manful CF, Sey AA, et al. Cannabis: a multifaceted plant with endless potentials. Front Pharmacol. 2023;14:1200269.","journal-title":"Front Pharmacol"},{"issue":"20","key":"1031_CR5","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790\u2013805.","journal-title":"Br J Pharmacol"},{"key":"1031_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/plants11212896","author":"C Maioli","year":"2022","unstructured":"Maioli C, Mattoteia D, Amin HIM, Minassi A, Caprioglio D. Cannabinol: history, syntheses, and biological profile of the greatest \u201cminor\u201d cannabinoid. Plants (Basel). 2022. https:\/\/doi.org\/10.3390\/plants11212896.","journal-title":"Plants (Basel)"},{"issue":"7","key":"1031_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101301","volume":"23","author":"F Shahbazi","year":"2020","unstructured":"Shahbazi F, Grandi V, Banerjee A, Trant JF. Cannabinoids and cannabinoid receptors: the story so far. iScience. 2020;23(7):101301.","journal-title":"iScience"},{"issue":"11","key":"1031_CR8","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477\u201382.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1031_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","volume":"46","author":"SM Stout","year":"2014","unstructured":"Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86\u201395.","journal-title":"Drug Metab Rev"},{"key":"1031_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900612","author":"RL Slaughter","year":"1995","unstructured":"Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995. https:\/\/doi.org\/10.1177\/106002809502900612.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"1031_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/JCP.0000000000001089","volume":"39","author":"Y Qian","year":"2019","unstructured":"Qian Y, Gurley BJ, Markowitz JS. The potential for pharmacokinetic interactions between cannabis products and conventional medications. J Clin Psychopharmacol. 2019;39(5):462\u201371.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"1031_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","volume":"79","author":"S Yamaori","year":"2010","unstructured":"Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol. 2010;79(11):1691\u20138.","journal-title":"Biochem Pharmacol"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lfs.2015.07.007","volume":"136","author":"S Yamaori","year":"2015","unstructured":"Yamaori S, Kinugasa Y, Jiang R, Takeda S, Yamamoto I, Watanabe K. Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Life Sci. 2015;136:87\u201393.","journal-title":"Life Sci"},{"issue":"11","key":"1031_CR14","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1124\/dmd.111.041384","volume":"39","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011;39(11):2049\u201356.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"1031_CR15","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351.","journal-title":"Epilepsia"},{"issue":"4","key":"1031_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","volume":"28","author":"R Jiang","year":"2013","unstructured":"Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"15-16","key":"1031_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","volume":"88","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15\u201316):730\u20136.","journal-title":"Life Sci"},{"issue":"4","key":"1031_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1208\/s12248-021-00616-7","volume":"23","author":"PT Doohan","year":"2021","unstructured":"Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization. AAPS J. 2021;23(4):91.","journal-title":"AAPS J"},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2174\/1389200033489424","volume":"4","author":"MJ Gomez-Lechon","year":"2003","unstructured":"Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as tools for studying drug toxicity and metabolism. Curr Drug Metab. 2003;4:292\u2013312.","journal-title":"Curr Drug Metab"},{"issue":"2","key":"1031_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100037","volume":"53","author":"A Balhara","year":"2025","unstructured":"Balhara A, Tsang YP, Unadkat JD. Cannabidiol and delta9-tetrahydrocannabinol induce drug-metabolizing enzymes, but not transporters, in human hepatocytes: implications for predicting complex cannabinoid-drug interactions. Drug Metab Dispos. 2025;53(2):100037.","journal-title":"Drug Metab Dispos"},{"key":"1031_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/16.5.276","author":"MA Huestis","year":"1992","unstructured":"Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992. https:\/\/doi.org\/10.1093\/jat\/16.5.276.","journal-title":"J Anal Toxicol"},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jpba.2012.10.016","volume":"74","author":"VC Pillai","year":"2013","unstructured":"Pillai VC, Strom SC, Caritis SN, Venkataramanan R. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS\/MS. J Pharm Biomed Anal. 2013;74:126\u201332.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"1031_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"5","key":"1031_CR24","first-page":"443","volume":"43","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003;43(5):443\u201369.","journal-title":"J Clin Pharmacol"},{"key":"1031_CR25","unstructured":"FDA. In vitro drug interaction studies\u2014Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. 2020."},{"issue":"6","key":"1031_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00228-023-03489-1","volume":"79","author":"A Alshabi","year":"2023","unstructured":"Alshabi A, Shaik IH, Zhao Y, Pillai VC, Caritis S, Venkataramanan R. A cocktail probe approach to evaluate the effect of hormones on the expression and activity of CYP enzymes in human hepatocytes with conditions simulating late stage of pregnancy. Eur J Clin Pharmacol. 2023;79(6):815\u201327.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"1031_CR27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1124\/dmd.113.052100","volume":"41","author":"VC Pillai","year":"2013","unstructured":"Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib\u2014An observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. Drug Metab Dispos. 2013;41(10):1843\u201351.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1031_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/cts.13448","volume":"16","author":"J Lee","year":"2023","unstructured":"Lee J, Fallon JK, Smith PC, Jackson KD. Formation of CYP3A-specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4\u03b2-hydroxycholesterol\/cholesterol ratio. Clin Transl Sci. 2023;16(2):279\u201391.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1031_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1517\/17425250903379546","volume":"6","author":"MA Perera","year":"2010","unstructured":"Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol. 2010;6(1):17\u201328.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00003088-200342020-00004","volume":"42","author":"MT Donato","year":"2003","unstructured":"Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet. 2003;42:153\u201378.","journal-title":"Clin Pharmacokinet"},{"key":"1031_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/B978-0-12-044620-9.50020-8","volume-title":"The cannabinoids: chemical, pharmacologic, and therapeutic aspects","author":"A Ohlsson","year":"1984","unstructured":"Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single dose kinetics of cannabidiol in man1. In: Agurell S, Dewey WL, Willette RE, editors. The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Academic Press; 1984. p. 219\u201325."},{"issue":"7","key":"1031_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","volume":"79","author":"MA ElSohly","year":"1995","unstructured":"ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995\u20132014): analysis of current data in the United States. Biol Psychiatry. 1995;79(7):613\u20139.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"1031_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/bms.1200140904","volume":"14","author":"E Johansson","year":"1987","unstructured":"Johansson E, Ohlsson A, Lindgren J-E, Agurell S, Gillespie H, Hollister LE. Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom. 1987;14(9):495\u20139.","journal-title":"Biomed Environ Mass Spectrom"},{"key":"1031_CR34","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/0006-2952(73)90028-2","volume":"22","author":"EG Leighty","year":"1973","unstructured":"Leighty EG. Metabolism and distribution of cannabinoids in rats after different methods of administration. Biochem Pharmacol. 1973;22:1613\u201321.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1031_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227\u201332.","journal-title":"Nat Rev Genet"},{"key":"1031_CR36","doi-asserted-by":"crossref","unstructured":"Roth MD. Induction of CYP1A1 by marijuana smoke and THC. Am J Respir Cell Mol Biol. 2001;24.","DOI":"10.1165\/ajrcmb.24.3.4252"},{"issue":"11","key":"1031_CR37","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/jps.2600681106","volume":"68","author":"WJ Jusko","year":"1979","unstructured":"Jusko WJ, Gardener MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates and ethanol. J Pharm Sci. 1979;68(11):1358\u201366.","journal-title":"J Pharm Sci"},{"key":"1031_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/BF00196109","volume":"46","author":"M Chetty","year":"1994","unstructured":"Chetty M, Miller R, Moodley SV. Smoking and body weight influence the clearance of chlorpromazine. Eur J Clin Pharmacol. 1994;46:523\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1031_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2133\/dmpk.DMPK-11-RG-107","volume":"27","author":"S Yamaori","year":"2012","unstructured":"Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet. 2012;27(3):294\u2013300.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"1031_CR40","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cpt.3504","volume":"117","author":"GC So","year":"2025","unstructured":"So GC, Lu JBL, Koyama S, et al. A phase I trial of the pharmacokinetic interaction between cannabidiol and tacrolimus. Clin Pharmacol Ther. 2025;117(3):716\u201323.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1031_CR41","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/ajt.15398","volume":"19","author":"AD Leino","year":"2019","unstructured":"Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant. 2019;19(10):2944\u20138.","journal-title":"Am J Transplant"},{"key":"1031_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nrd1851","volume":"4","author":"LC Wienkers","year":"2005","unstructured":"Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4:825\u201333.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1031_CR43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","volume":"35","author":"JH Lin","year":"1998","unstructured":"Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35(5):361\u201390.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1031_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.apsb.2012.10.004","volume":"2","author":"D Zhang","year":"2012","unstructured":"Zhang D, Luo G, Ding X, Lu C. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B. 2012;2(6):549\u201361.","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"1031_CR45","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1124\/dmd.121.000442","volume":"49","author":"S Nasrin","year":"2021","unstructured":"Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab Dispos. 2021;49(12):1070\u201380.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1031_CR46","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1124\/dmd.121.000530","volume":"49","author":"S Nasrin","year":"2021","unstructured":"Nasrin S, Watson CJW, Bardhi K, Fort G, Chen G, Lazarus P. Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites. Drug Metab Dispos. 2021;49(12):1081\u20139.","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01031-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:51:23Z","timestamp":1787903483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01031-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":46,"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01031-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: N.C., A.J., and R.V. Data curation: N.C. and I.H.S. Formal analysis: N.C. and I.H.S. Investigation: N.C. Methodology: N.C. and A.J. Validation: N.C. Visualization: N.C. and I.H.S. Writing\u2014original draft: N.C. Writing\u2014review and editing: N.C., I.H.S., S.C., M.K., and R.V. Supervision: I.H.S. and R.V. Funding acquisition: R.V.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}